Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems

Actas Dermosifiliogr. 2024 Jan;115(1):T88-T90. doi: 10.1016/j.ad.2023.10.010. Epub 2023 Oct 21.

[Article in English, Spanish]

Authors

J Sánchez¹, L Alvarez², J F López³

Affiliations

¹ Group of Clinical and Experimental Allergy, University of Antioquia, IPSU clinic, Medellín, Colombia. Electronic address: jorgem.sanchez@udea.edu.co.
² Pharmacoeconomic evaluation group, SURA Company.
³ Group of Clinical and Experimental Allergy, University of Antioquia, IPSU clinic, Medellín, Colombia.

PMID: 37871896
DOI: 10.1016/j.ad.2023.10.010

No abstract available

Publication types

Case Reports

MeSH terms

Anti-Allergic Agents* / therapeutic use
Chronic Disease
Chronic Urticaria* / drug therapy
Humans
Omalizumab / therapeutic use
Treatment Outcome
Urticaria* / diagnosis
Urticaria* / drug therapy

Substances

Omalizumab
Anti-Allergic Agents